GlucoTrack Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Paul Goode

Algemeen directeur

US$483.2k

Totale compensatie

Percentage CEO-salaris	46.6%
Dienstverband CEO	less than a year
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	2.2yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

GlucoTrack to start R&D program for glucose monitoring system

Oct 10

Analyse CEO-vergoeding

Hoe is Paul Goode's beloning veranderd ten opzichte van GlucoTrack's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$15m
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$483k	US$225k	-US$8m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$6m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	US$540k	US$201k	-US$4m
Sep 30 2022	n/a	n/a	-US$5m
Jun 30 2022	n/a	n/a	-US$5m
Mar 31 2022	n/a	n/a	-US$4m
Dec 31 2021	US$29k	n/a	-US$4m
Sep 30 2021	n/a	n/a	-US$3m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$3m
Dec 31 2020	US$1k	n/a	-US$3m

Compensatie versus markt: De totale vergoeding ($USD 483.24K ) Paul } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: De vergoeding van Paul is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Paul Goode (56 yo)

less than a year

Tenure

US$483,243

Compensatie

Mr. Paul V. Goode, Ph D., serves as Chief Executive Officer and President at GlucoTrack, Inc and also serves as its Director since September 2024. He served as President and Chief Operating Officer at Gluc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Goode	CEO, President & Director	no data	US$483.24k	0.23% $ 6.5k
Mark Tapsak	Vice President of Technology	2.2yrs	US$176.21k	0.11% $ 3.2k
Drinda Benjamin	Vice President of Marketing	1.3yrs	geen gegevens	0.0073% $ 206.1
James Thrower	Vice President of Engineering	no data	US$264.11k	0.015% $ 412.6
Avner Gal	Co-Founder	23.8yrs	US$187.39k	geen gegevens
David Malka	Co-Founder	23.8yrs	US$199.35k	geen gegevens
James Cardwell	Chief Financial Officer	1.1yrs	geen gegevens	geen gegevens

2.2yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GCTK wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Goode	CEO, President & Director	less than a year	US$483.24k	0.23% $ 6.5k
Avner Gal	Co-Founder	7.7yrs	US$187.39k	geen gegevens
Luis Malave	Independent Chairman	3.4yrs	US$70.00k	0.21% $ 5.8k
Irl Hirsch	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Robert Fischell	Independent Director	14.8yrs	US$70.00k	0.10% $ 2.8k
Lutz Heinemann	Member of Scientific & Clinical Advisory Board	9.8yrs	geen gegevens	geen gegevens
Barry Ginsberg	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Allen Danzig	Independent Director	5.1yrs	US$70.00k	0.078% $ 2.2k
David Klonoff	Chair of Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Erin Carter	Independent Director	1.3yrs	US$23.33k	0.25% $ 7.1k
Michael Heise	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Jan Bolinder	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GCTK wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

GlucoTrack Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Glucotrack, Inc. Appoints John Ballantyne to Its Board of Directors

Glucotrack Announces the Appointment of Andy Balo to Board of Directors

GlucoTrack, Inc., Annual General Meeting, Apr 26, 2024

Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors

GlucoTrack, Inc. Announces Executive Changes

Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee

Recent updates

GlucoTrack, Inc. has completed a Follow-on Equity Offering in the amount of $9.995237 million.

Glucotrack, Inc. Appoints John Ballantyne to Its Board of Directors

GlucoTrack, Inc. announced that it has received $0.1 million in funding

Glucotrack Announces the Appointment of Andy Balo to Board of Directors

Glucotrack Reports Successful Completion of First Reported Long-Term Preclinical Study of Its Epidural Glucose Monitoring Sensor

Glucotrack, Inc Announces 90-Day Preclinical Study Results That Demonstrate Sustained Accuracy of Its Implantable Continuous Blood Glucose Monitor

GlucoTrack Receives a Third Letter from Nasdaq Notifies Not Regains Compliance with the Minimum Bid Price Requirement During the Extended Compliance Period

Glucotrack’s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study

Glucotrack Announces Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Requirement

GlucoTrack, Inc. announced that it has received $0.5 million in funding

GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring

Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor

GlucoTrack, Inc., Annual General Meeting, Apr 26, 2024

Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors

GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor

GlucoTrack, Inc. Announces Executive Changes

Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee

Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor

GlucoTrack Receives Letter from Nasdaq Regarding No Longer Complies with Nasdaq's Listing Rule 5550(a)(2)

Nasdaq Issues a Letter to GlucoTrack Granting an Extension Until May 22, 2023 to Obtain Compliance

Glucotrack to Begin Research & Development of Novel Continuous Glucose Monitoring System

GlucoTrack to start R&D program for glucose monitoring system

GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor

Shalom Shushan, Chief Technology Officer, Provides Notice of His Resignation from Glucotrack, Inc., Effective May 22, 2022

Integrity Applications, Inc. announced delayed 10-Q filing

Integrity Applications, Inc. announced delayed annual 10-K filing

Integrity Applications, Inc. Announces Executive Changes

Integrity Applications Appoints Paul V. Goode to Board of Directors

Integrity Applications, Inc. Appoints Shalom Shushan as Chief Technology Officer, Effective November 9, 2020

Integrity Applications, Inc. Announces Resignation of Eugene Naidis as Vice President of R&D, Effective December 31, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd